Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients
A recent phase II clinical trial results suggest that the monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.
Read Original Article: Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients »
